ALPHA3 Explores LBCL First-Line Consolidation With Off-the-Shelf Cema-Cel

For many patients with diffuse large B-cell lymphoma (DLBCL), completing frontline chemoimmunotherapy and achieving a PET-negative remission is not always the end of the story—approximately 1 in 5 will still relapse despite an apparently complete response.

This has driven growing interest in whether treatment decisions should be guided not only by imaging, but also by more sensitive measures of minimal residual disease (MRD), which can reveal ongoing molecular disease even when scans appear clean. The ongoing phase 2 ALPHA3 trial (NCT06500273) builds on this concept by testing whether intervening with cemacabtagene ansegedleucel (cema-cel), a CD19-directed, allogeneic chimeric antigen receptor T-cell (CAR T) therapy, in MRD-positive patients after first-line treatment can deepen remissions and potentially improve long-term cure rates.^1,2 Because the approach uses an off-the-shelf cell product, it also raises important questions about how such therapies could be integrated into practice beyond academic centers.

In an interview with Targeted Oncology, Jeff Sharman, MD, chair, Lymphoma Research Executive Committees, SCRI at Willamette Valley Cancer Institute & Research Center, discussed the rationale for ALPHA3, interim data from the trial’s futility analysis, and the practical implications of delivering this off-the-shelf therapy in community oncology settings.

Targeted Oncology: What was the rationale for the ALPHA3 study and the futility analysis?

Jeff Sharman, MD: This is a large randomized, prospective phase [2] study in DLBCL. This is a disease where typically we treat patients with 6 cycles of chemoimmunotherapy, get a PET/CT scan at the end of treatment, and if somebody's PET-negative, we then observe over the ensuing several years. Ideally, they don't have relapse during that period of time, and if they have a PET-negative response, there's a reasonable chance they're cured, but 1 in 5 patients will still likely experience a relapse. Newer molecular tests that can be drawn from the blood leveraging circulating tumor DNA appear to be able to help discriminate those patients who are likely cured vs those who are likely to relapse, and that's raised the question whether or not we could introduce consolidation therapy at the end of treatment to improve those rates of cure.

To that end, this was a study where…an interim analysis was conducted, more than anything, looking for futility; [in other words], does it make sense to continue the study? In the material that was presented publicly, 24 patients, 12 in each arm, were evaluated. These were patients who'd been diagnosed with LBCL, undergone chemoimmunotherapy, and had a negative PET scan or an equivocal PET scan for which observation was suitable. They were then subjected to molecular DNA testing, and they were found to be at high risk for relapse. Half of them were observed; half of them were treated with cema-cel, which is the experimental product.

What were the findings of the futility analysis?

What was found was that among the patients who tested positive and were observed, subsequent sequential testing generally showed rising rates of MRD levels, suggestive of disease that was persistent and emerging or regrowing. Then, amongst the patients who were MRD-positive and treated with cema-cel, 7 out of 12 cleared their MRD status. And I should say, within the control arm, there are 2 patients as well who controlled their disease status. But overall, there was a pretty significant difference between the 2, percentage wise… there was a delta between the 2 groups of about a little over 40%. We'll have to see whether or not that ends up resulting in a clinical difference in outcomes between these 2 patient [groups], but at least it validates the hypothesis and says to the participating investigators and sponsors that we continue with the study.

How does the safety profile so far in this setting compare with that of autologous CAR T?

This is a very different setting to use CAR T-cell therapy. Normally, CAR T is administered in a patient who has relapsed disease that is positive on imaging and biopsy—macroscopic disease, if you will. And it may very well be that amongst those patients with more active disease, that [adverse] effects [AEs] that are common to CAR T, including cytokine release syndrome [CRS] and immune effector cell-associated neurologic syndrome [ICANS], may be driven more by the expansion and propagation of the cells in response to the presence of active bulk disease. This is being given in a different setting…where patients actually don't have bulk disease; they have PET-negative scans, yet their MRD testing came up positive. And what's interesting is we do see that even in the 12 patients treated with cema-cel, we did not observe any CRS or ICANS, which is very different than what you would expect for autologous CAR T in patients with bulk relapsed disease.

I'll add to that, AEs were fairly typical [and] quite well tolerated. There were things you might expect in this population, some infections for patients who've just completed chemoimmunotherapy. The treatment was almost entirely given in the outpatient setting. I think there were a limited number of hospitalizations, but they were for circumstances deemed unrelated to the therapy when they were admitted. So…a very reassuring safety profile amongst the 12 patients evaluated thus far.

The study included a meaningful proportion of patients treated in community cancer centers. What does this experience suggest about the feasibility of administering allogeneic CAR T in the community setting?

With autologous CAR T, there are several barriers to implementation in community practice settings. First is that you need a hospital partner that is agreeable to participating in this. And these are for autologous CAR T; these are very expensive products. And so, if the oncology group isn't part of the hospital, that can present some problems. For those independent groups, cost of acquisition of the drug represents a significant financial risk and reimbursement. It's a lot of additional work. These things require single case agreements in many cases, and that requires a lot of infrastructure. In addition, patients need leukapheresis, which oftentimes isn't broadly available and needs to be secured. And then patients need manufacturing of the CAR T often at a time when they're really quite sick. So [allogeneic CAR T] solves a lot of those issues, because there's no patient-specific manufacturing; this is an off-the-shelf product.

Secondly, we don't know enough about cost yet to know, but logistically, sites receive a cryopreserved sample in a Dewar [container]. They just allow these to thaw at room temperature, and then they're administered [intravenously] following lymphodepletion therapy that are relatively simple drugs that oncologists have used for a long time. I'm a community practice doctor, and a number of my colleagues within our network have participated in this study and found that it's entirely something that can be logistically administered within the community without any significant barriers or challenges.

What logistical or infrastructure requirements should community practices be thinking about now if allogeneic CAR T therapies move closer to approval?

I think if these are approved, it's not going to be a heavy lift from the practical administrative side; that part was relatively straightforward. The cells can arrive and remain cryopreserved for several days before administration. I think that the challenges that we don't know about yet are going to be cost of administration, insurance authorization, whether there's REMS [Risk Evaluation and Mitigation Strategies] programs—things that that we don't really have any ability to know about. Right now, you don't necessarily have to be FACT [Foundation for the Accreditation of Cellular Therapy]-accredited for autologous CAR T but from a payer perspective, sometimes these things are potential challenges. So, I think some of the potential challenges remain to be seen; however, many of the known challenges are adequately addressed.

Looking ahead, where do you see the role of allogeneic CAR T fitting into the broader LBCL treatment paradigm?

I think that within the lymphoid malignancy space, we've not only seen autologous CAR T; we've seen bispecifics, and now we could potentially be seeing allogeneic CAR T. I think that oncology practices are simply going to have to make the adjustments to be able to deliver these therapies, because we know that right now, only about 1 in 5 patients eligible for autologous CAR T are even getting it. And that, I think, speaks to the barriers of autologous CAR T. Maybe this product eliminates some of the barriers, maybe most of the barriers; I think time’s yet to tell. But if only 1 out of 5 eligible patients is getting CAR T, that means it's a dramatically underutilized therapy, and one in need of significantly more accessibility. And I do think that this product probably addresses a number of those shortfalls.

REFERENCES

1. Allogene Therapeutics reports interim futility analysis from pivotal ALPHA3 trial showing 58.3% MRD clearance with cemacabtagene ansegedleucel (cema-cel) vs. 16.7% in observation arm in first-line consolidation LBCL. News release. Allogene Therapeutics. April 13, 2026. Accessed May 7, 2026. https://tinyurl.com/3e7bvn56

2. Consolidation of first-line MRD+ remission with cema-cel in patients with LBCL (ALPHA3). ClinicalTrials.gov. Updated March 18, 2026. Accessed May 7, 2026. https://clinicaltrials.gov/study/NCT06500273